Fig. 2From: ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE studyMedian blood eosinophil count (cells/mm3) recorded at the index date (week 0) and during benralizumab treatment, up to week 48Back to article page